 |
|
|
|
 |
|
|
| Article 1 to 10 out of 10 concerning INEX Pharmaceuticals Corporation
|
-
INEX and Alnylam Announce Allowance of New U.S. Patent Covering Delivery of RNAi Therapeutics
(03/09/2007)
New Patent Broadly Covers Delivery of RNAi Therapeutics with Cationic Liposomes
Inex Pharmaceuticals Corporation and Alnylam Pharmaceuticals, Inc. announced that the United States Patent and Trademark Office (USPTO) has allowed claims in a patent application that covers nucleic acid-lipid compositions, including cationic ...
-
Inex Pharmaceuticals Submits Petition Against Protiva Biotherapeutics
(02/27/2007)
Inex Pharmaceuticals Corporation announced that it has submitted a petition for filing in the Supreme Court of British Columbia seeking to have Protiva Biotherapeutics Inc. ("Protiva") declared bankrupt and that a bankruptcy order be made in respect ...
-
Inex Pharmaceuticals Announces Appeal Date for Spin-out of Tekmira Pharmaceuticals
(01/18/2007)
Inex Pharmaceuticals Corporation announced that on February 6, 2007 the British Columbia Court of Appeal will hear Protiva Biotherapeutics, Inc. ("Protiva") appeal of the Supreme Court of British Columbia's ruling that approved the INEX Plan of ...
-
Inex Pharmaceuticals Receives Positive Court Outcome for Spin-out of Tekmira
(11/28/2006)
INEX Pharmaceuticals Corporation announced that the British Columbia Supreme Court issued a favourable written ruling from the November 7 and 8, 2006 hearing with respect to the spin-out of Tekmira Pharmaceuticals Corporation ("Tekmira"). In its ...
-
Commencement of INX-0125 Phase 1 Clinical Trial Triggers US$1.0 Million Milestone Payment to INEX
(09/01/2006)
Inex Pharmaceuticals Corporation announced that its partner Hana Biosciences has enrolled the first patient in a Phase 1 human clinical trial evaluating the safety, tolerability and preliminary efficacy of INX-0125 (sphingosomal vinorelbine) as a ...
-
INEX Seeks Approval to Spin-Out Assets Into Tekmira Pharmaceuticals
(08/28/2006)
Inex Pharmaceuticals Corporation announced that it has filed with securities regulators in Canada and mailed to shareholders the information circular and proxy materials for the shareholders' meeting September 20, 2006 at which INEX will seek ...
-
Inex Pharmaceuticals Closes Hana Biosciences Licensing Agreement
(05/10/2006)
Inex Pharmaceuticals Corporation announced that it has closed the previously announced transaction to license three products from its Targeted Chemotherapy pipeline to Hana Biosciences, Inc. INEX has granted Hana a worldwide license to develop and ...
-
Hana Bioscience to license three targeted cancer drug candidates from Inex Pharmaceuticals
(03/21/2006)
Hana Biosciences signed a letter of intent to license the worldwide rights to develop and commercialize three novel targeted chemotherapy drug candidates for the treatment of solid and hematological cancers from Inex Pharmaceuticals Corporation. The ...
-
INEX to Spin Off Targeted Immunotherapy Assets
(11/21/2005)
Inex Pharmaceuticals Corporation announced that its Board of Directors has approved a Company reorganization that would include the spin-off of its Targeted Immunotherapy technology and product candidates into a new company. If the proposal is ...
-
Enzon annouces termination of agreements with Inex
(03/21/2005)
Enzon Pharmaceuticals, Inc. announced that it has entered into an agreement with INEX Pharmaceuticals Corporation to terminate the companies' partnership for the development and commercialization of INEX's proprietary oncology product, MARQIBOŽ ...
|
|
|
|
|
Top
